KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Shares Outstanding (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Shares Outstanding data on record, last reported at $18.3 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.39% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $18.3 million, up 3.39%, while the annual FY2025 figure was $18.3 million, 3.39% up from the prior year.
  • Shares Outstanding reached $18.3 million in Q4 2025 per RIGL's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $172.8 million in Q2 2022 and bottomed at $17.2 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $63.8 million, with a median of $17.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: tumbled 89.91% in 2023, then grew 3.39% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $17.2 million in 2021, then increased by 1.05% to $17.3 million in 2022, then grew by 0.82% to $17.5 million in 2023, then increased by 1.3% to $17.7 million in 2024, then rose by 3.39% to $18.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $18.3 million in Q4 2025, $18.1 million in Q3 2025, and $17.9 million in Q2 2025.